Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2021 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
August 02, 2021 16:04 ET
|
Oncternal Therapeutics
SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced...
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
July 29, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
July 01, 2021 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2021 16:05 ET
|
Oncternal Therapeutics
SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Oncternal Therapeutics
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced...
Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021
May 19, 2021 17:30 ET
|
Oncternal Therapeutics
Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released todayTwo patients who achieved a complete...
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021
May 19, 2021 17:01 ET
|
Oncternal Therapeutics
Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in...
Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
May 17, 2021 16:01 ET
|
Oncternal Therapeutics
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...
Oncternal Provides Business Update and Announces First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Oncternal Therapeutics
Interim results of a Phase 1b trial of cirmtuzumab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel...